Archon Biosciences
Seattle, Washington, United States · Artificial Intelligence, Biotechnology, Health Care · 50 employees
Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nano
Funding history
- Series seed — $20.0M — Oct 2024
Recent signals
- Oct 30, 2024: Launched Archon Biosciences Launches Innovative Antibody Cages to Revolutionize Drug Development with AI-driven Protein Design
- Oct 30, 2024: Raised $20.0M in Series seed
See plans & pricing → Track Archon Biosciences’s funding, hiring, and signals — with verified contacts — on Fundz.